Extracellular vesicles, non-coding RNAs, oncology, biomarkers, carbonic anhydrases
cancer cell lines, primary cell cultures (breast, colorectal cancer, fibroblasts), 3-D cell cultures, patient samples
Isolation and characterisation of extracellular vesicles (EVs), analysis of RNA and DNA content in EVs, EV uptake, Ion Torrent PGM and Proton sequencers, microarrays, real-time PCR, siRNA, IHC, ICC, FACS, in vitro assays: MTT, proliferation, spheroid formation, invasion, migration, cell cycle.
Collaboration with oncology clinics for Cancer Biobanking (tissues, serum/plasma, follow-up info). Ongoing collaboration projects on cancer-derived EVs as biomarkers and drug targets for prostate, breast and gastrointestinal cancers. Collaboration with organic chemists on epigenetic drug testing.
Characterization of RNA and DNA content in EVs produced by breast, gastrointestinal and prostate cancers in order to assess to what extent the EV content reflect the genetic make-up of cancer cells and whether or not they can be exploited for detecting intratumoural heterogeneity of cancers. Another aspect of this study is to gain insight into cancer-derived EV tropism, biodistribution and functional effects on cancer-cancer and cancer-host crosstalk. Furthermore, we are interested in the impact of extracellular acidity on the functional phenotype of tumour infiltrating immune cells, CAIX as a drug target to abrogate immunosuppressive microenvironment and in inducing the formation of tertiary lymphoid structures (TLS) in the tumour microenvironment as a putative therapeutic strategy.
Alternate member of Committee for Advanced Therapies (CAT), European Medicines Agency (EMA) Editorial board member of Biomarkers in Cancer, Central European Journal of Biology, Journal of Circulating Biomarkers